Document:

DESCRIPTION
        OF ADVANCES MADE BY 

      CYBERDEFENDER
        CORPORATION TO IGOR BARASH

      

      In
        2005
        CyberDefender Corporation (the “Company”) made a series of advances to Mr. Igor
        Barash for personal expenses which advances totaled $6,285. These
        were
        non-business related expenses charged to the Company’s credit card. There was no
        formal written agreement between Mr. Barash and the Company relating to
        repayment of these advances and the advances did not accrue interest.
As
        of
        September 30, 2006, all advances were either repaid or reclassified as salary.
        Since October 1, 2006, no further advances have been made to Mr.
        Barash.AMENDMENT
      NO. 1 TO

    SHAREHOLDER
      RIGHTS AGREEMENT

     

    Amendment No.
      1, dated as of January 24, 2007 (the “Amendment”), to the Shareholder Rights
      Agreement, dated as of October 8, 2002 (the “Rights Agreement”), by and
      between DOV Pharmaceutical, Inc., a Delaware corporation (the “Company”), and
      Continental Stock Transfer & Trust Co., a federally chartered trust
      company (the “Rights Agent”).

     

    WITNESSETH

    

    WHEREAS,
      pursuant to Section 27 of the Rights Agreement, the Company may prior to a
      Section 11(a)(ii) Event (as defined in the Rights Agreement) supplement or
      amend
      the Rights Agreement without the approval of any holders of certificates
      representing shares of common stock of the Company or any other securities
      of
      the Company; and

    

    WHEREAS,
      the Company now desires to amend the Rights Agreement as set forth in this
      Amendment, and pursuant to Section 27 of the Rights Agreement, the Board of
      Directors of the Company hereby directs that the Rights Agreement should be
      amended as set forth in this Amendment.

    

    NOW,
      THEREFORE, in consideration of the premises and the mutual agreements herein
      set
      forth, the parties hereby agree as follows:

    

    1. Amendments
      to Section 1.

    

    (a) Section
      1
      of the Rights Agreement is hereby amended by adding the following
      definitions:

    

    (ll)
       “Debentures”
shall
      mean the Company’s 2.50% Convertible Subordinated Debentures due 2025, issued
      under that certain Indenture, dated as of December 22, 2004, by and between
      the Company and Wells Fargo Bank, National Association, as Trustee.

    

    (mm) “Exchange
      Offer”
shall
      have the meaning set forth in the Restructuring Support Agreement.

    

    (nn) “Noteholders”
shall
      mean the holders of the Debentures.

    

    (oo) “Restructuring
      Support Agreement”
shall
      mean the Restructuring Support Agreement, dated as of January 24, 2007, by
      and among the Company and certain Noteholders named therein, as amended from
      time to time.

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (b) The
      definition of “Acquiring
      Person”
in
      Section 1(a) of the Rights Agreement is hereby amended by inserting the
      following sentence at the end thereof:

    

    
      	 	 	
              “Notwithstanding
                the foregoing or any other provision of this Agreement to the contrary,
                none of (i) the negotiation, execution and delivery of the Restructuring
                Support Agreement or any other documents referred to therein, (ii)
                the
                exercise by the parties thereto of their respective rights under
                the
                Restructuring Support Agreement or any other documents referred to
                therein, and (iii) the consummation of the Exchange Offer or any
                of the
                other transactions contemplated by the Restructuring Support Agreement,
                shall be deemed to result in any Noteholder or any other Person becoming
                an Acquiring Person.”

            

    

    

    2. Amendment
      to Section 3(a).
      Section
      3(a) of the Rights Agreement is hereby amended to add the following sentence
      at
      the end thereof:

    

    
      	 	 	
              “Notwithstanding
                anything in this Agreement to the contrary, a Distribution Date shall
                not
                be deemed to have occurred as a result of any of (i) the negotiation,
                execution and delivery of the Restructuring Support Agreement or
                any other
                documents referred to therein, (ii) the exercise by the parties thereto
                of
                their respective rights under the Restructuring Support Agreement
                or any
                other documents referred to therein, and (iii) the consummation of
                the
                Exchange Offer or any of the other transactions contemplated by the
                Restructuring Support Agreement.”

            

    

    

    3. Effectiveness.
      This
      Amendment shall be deemed effective as of the date first above written, as
      if
      executed on such date. Except as expressly set forth herein, this Amendment
      shall not by implication or otherwise alter, modify, amend or in any way affect
      any of the terms, conditions, obligations, covenants or agreements contained
      in
      the Rights Agreement, all of which are ratified and affirmed in all respects
      and
      shall continue in full force and effect and shall be otherwise
      unaffected.

    

    4. Governing
      Law.
      This
      Amendment shall be deemed to be a contract made under the laws of the State
      of
      Delaware and for all purposes shall be governed by and construed in accordance
      with the laws of such state applicable to contracts to be made and performed
      entirely within such state.

    

    5. Counterparts.
      This
      Amendment may be executed in any number of counterparts, each of which shall
      for
      all purposes be deemed an original, and all of which together shall constitute
      but one and the same instrument.       

     

    [REMAINDER
      OF PAGE INTENTIONALLY LEFT BLANK]

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    IN
      WITNESS WHEREOF, the parties hereto have caused this Amendment No. 1 to
      Shareholder Rights Agreement to be duly executed as of the day and year first
      above written. 

     

    
      	 	 	 
	 	
              DOV
                PHARMACEUTICAL, INC.

            
	 
 	 
 	 
 
	
            	By:  	/s/ Barbara
              Duncan
	 	
              

              Barbara
                Duncan

            
	 	President
              and
              Chief Financial Officer

    
      	 	 	 
	 	
              CONTINENTAL
                STOCK TRANSFER & TRUST CO.,

            
	 	
              as
                Rights Agent 

            
	 
 	 
 	 
 
	
            	By:  	/s/ Felix
              Orihuela
	 	
              

              Name:
                Felix Orihuela   

            
	 	
              Title:
                Vice President

            

    

     

    
      
        
        

      

      
        3Unassociated Document

    AMENDED
      AND RESTATED LICENSE AGREEMENT

    (Bicifadine
      - CL220,075)

     

    THIS
      AGREEMENT (this “Agreement”)
      is
      entered into on this 7th day of December 2006 (the “Signature
      Date”)
      and is
      effective as of May 29, 1998 (the “Effective
      Date”)
      by and
      between DOV PHARMACEUTICAL, INC., a corporation organized and existing under
      the
      laws of the State of Delaware, having its registered offices at 150 Pierce
      St.,
      Somerset, New Jersey 08873 (hereinafter “DOV”)
      on the
      one hand and WYETH
      HOLDINGS CORPORATION (formerly known as “American Cyanamid Company”), a
      corporation organized under the laws of the State of Maine, U.S.A., having
      its
      principal place of business at 5 Giralda Farms, Madison, New Jersey 07940,
      U.S.A. (hereinafter,
      “WHC”)
      and
      WYETH, acting through its Wyeth Pharmaceuticals Division, a corporation
      organized under the laws of the State of Delaware, U.S.A., having its principal
      place of business at 5 Giralda Farms, Madison, New Jersey 07940, U.S.A.
      (hereinafter “Wyeth
      Pharmaceuticals”),
      on
      the other hand. WHC and Wyeth Pharmaceuticals may individually and collectively,
      as the context requires, be referred to herein as “Wyeth".

     

    WITNESSETH:

     

    WHEREAS,
      DOV and Wyeth entered into that certain License Agreement dated May 29, 1998
      (as
      previously amended, the “Original
      License Agreement”)
      pursuant to which Wyeth granted to DOV a worldwide exclusive license under
      the
      ACY Patents and the ACY Know-How (as such terms are defined therein) for a
      group
      of four (4) specified compounds;

     

    WHEREAS,
      DOV and Wyeth entered into that certain Amended and Restated License Agreement
      dated February 25, 2004 (the “Prior
      Amended and Restated License Agreement”)
      pursuant to which (i) Wyeth and DOV amended and restated the Original
      License Agreement so as to remove from such agreement the rights and licenses
      granted to DOV and the other rights and obligations of each of the parties
      thereunder, in each case, which rights, licenses and obligations relate to
      the
      compound designated as CL 285,489 (also known as Indiplon) and to modify
      the consideration payable by DOV to Wyeth thereunder with respect to each
      Product other than CL 285,489 and (ii) at the time the Prior Amended
      and Restated License Agreement was entered into by the parties, the parties
      also
      entered into a separate license agreement providing for the grant of a
      worldwide, exclusive license to DOV under certain intellectual property rights
      of Wyeth for the development and commercialization of CL 285,489 and setting
      forth the rights and obligations of the parties with respect
      thereto;

     

    WHEREAS,
      DOV and Wyeth now desire to amend and restate the Prior Amended and Restated
      License Agreement so as to remove from such agreement, and reflect in two
      separate agreements, the rights and licenses granted to DOV and the other rights
      and obligations of each of the parties thereunder, in each case, which rights,
      licenses and obligations relate to the compounds designated as CL 216,303
& CL 273,547, and to modify the rights and obligations of the parties
      with respect to CL 220,075 (also known as “Bicifadine”)
      contained herein;

     

    WHEREAS,
      Wyeth possesses intellectual property rights relating to the chemical compound
      designated as Bicifadine and listed in Schedule
      1
      attached
      hereto and made a part hereof and to pharmaceutical products to be processed
      from the aforesaid compound;

     

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

    

     

    WHEREAS,
      Wyeth designates Wyeth Pharmaceuticals, an Affiliate of Wyeth, with principal
      offices at 500 Arcola Road, Collegeville, Pennsylvania 19426, U.S.A., as the
      correspondent and contact for day-to-day business regarding the compounds that
      appear in Schedule
      1.
      All
      correspondence and contacts shall be with Wyeth Pharmaceuticals.

     

    WHEREAS,
      DOV is interested to develop as well as manufacture, have manufactured, use,
      and
      sell pharmaceutical products containing Bicifadine worldwide under licenses
      that
      Wyeth is willing to grant.

     

    NOW,
      THEREFORE, in consideration of the premises and the mutual covenants and
      agreements set forth herein, the parties hereto agree as follows:

     

    Article
      1.0  Definitions

     

    
      	1.1.     
                 	
              “Affiliate”
                means with respect to a party, any other business entity that directly
                or
                indirectly controls, is controlled by, or is under common control
                with,
                such party. A business entity or party shall be regarded as in control
                of
                another business entity if it owns, or directly or indirectly controls,
                at
                least fifty percent (50%) of the voting stock or other ownership
                interest
                of the other business entity, or if it directly or indirectly possesses
                the power to direct or cause the direction of the management and
                policies
                of the other business entity by any means
                whatsoever.

            

    

     

    
      	1.2.      
                	
              “Control”
                or “Controlled”
                means, with respect to any intellectual property right, possession
                of the
                ability to grant the other party access, a license or sublicense
                (as
                applicable) as provided for herein without violating the terms of
                any
                agreement or other arrangement with any third party existing at the
                time
                such party would be first required hereunder to grant the other party
                such
                access, license or sublicense.

            

    

     

    
      	1.3.      
                	
              “DOV
                Patents”
                means (i) the patents and patent applications listed in Exhibit B,
                all patents issuing on such patent applications, plus all other Patents
                Rights that claim priority to, in whole or in part, directly or
                indirectly, one or more of any such patents or patent applications,
                plus
                (ii) all other Patent Rights Controlled by DOV or any of its Affiliates,
                as of the Effective Date or thereafter during the term of this Agreement,
                that are necessary for the manufacture, use sale, offer for sale,
                importation, research, development or commercialization or other
                exploitation of any Product or Marketed Product solely for use in
                the
                Retained Rights Field,
                provided, however,
                that for this clause (ii) such other Patent Rights shall not
                include (1) any Patent Right directed to or claiming any
                manufacturing technology that is not required for the manufacture
                of such
                Product or Marketed Product (e.g.,
                if the Product or Marketed Product is amenable to being manufactured
                by a
                method that is not covered by the applicable other Patent Right,
                such
                other Patent Right would not be considered to be a DOV Patent for
                purposes
                of this Agreement) or (2) any Patent Right directed to or claiming
                any pharmaceutical formulation
                technology.

            

    

     

    
      	1.4.      
                	
              “Field”
                means the treatment of any diseases, disorders and conditions in
                humans,
                other than any disease, disorder or condition within the Retained
                Rights
                Field.

            

    

     

    
      	1.5.       
               	
              “Marketed
                Product”
                means a pharmaceutical preparation in finished form containing Product
                suitable for human administration, whether alone or in combination
                with
                other active ingredients.

            

    

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    
      	1.6.       
               	
              “Net
                Sales”
                shall mean the gross amount invoiced for the Marketed Product sold,
                distributed or otherwise disposed of by DOV and/or its Affiliates
                or its
                sublicensees (including any further sublicensees), in an arm’s length
                transaction to an end user (“Gross
                Sales”),
                less:

            

    

     

    
      	(i)        
                	
              transportation
                charges or allowances, if any, included in such
                price;

            

    

     

    
      	(ii)       
               	
              trade,
                quantity or cash discounts, service allowances and broker’s or agent’s
                commissions, but not salaries, commissions, bonuses or other incentive
                pay
                to in-house sales or other personnel if any, allowed or
                paid;

            

    

     

    
      	(iii)       
               	
              credits
                or allowances, if any, given or made on account of price adjustments,
                returns, bad debts, off-invoice promotional discounts, rebates, and
                any
                all Federal, state or local government rebates whether in existence
                now or
                enacted at any time during the term of this Agreement (e.g.,
                HCFA or Medicaid rebates), rejections, recalls or destruction requested
                or
                made by an appropriate government agency;
                and

            

    

     

    
      	(iv)      
               	
              any
                tax, excise or governmental charge upon or measured by the sale,
                transportation, delivery or use of the Marketed Product;
                

            

    

     

    provided
      that Net Sales shall in no event be less than eighty percent (80%) of Gross
      Sales.

     

    In
      the
      case of discounts on “bundles” of products which include the Marketed Product,
      DOV, its Affiliates and its sublicensees (including further sublicensees) may,
      with notice to Wyeth, calculate Net Sales as set forth above discounting the
      bona fide list price of the Marketed Product by the average percentage discount
      of all products of the selling party and/or its Affiliates or sublicensees
      in a
      particular “bundle”, calculated as follows:

     

    Average
      percentage 

    discount
      on a =
      (1-A/B)
      x 100

    particular
      “bundle”

     

    where
      A
      equals the total discounted price of a particular “bundle” of products, and B
      equals the sum of the undiscounted bona fide list prices of each unit of every
      product in such “bundle”. DOV shall provide Wyeth documentation, reasonably
      acceptable to Wyeth, establishing such average discount with respect to each
      “bundle”. Where the Marketed Product is also sold other than in bundled form,
      the average discount as calculated above shall be applied to the undiscounted
      list price of the Marketed Product in the “bundle”. If the Marketed Product is
      not sold separately and no bona fide list price exists for the Marketed Product,
      the parties shall negotiate in good faith an imputed list price for the Marketed
      Product, and the average discount as calculated above with respect thereto
      shall
      be applied to such imputed list price.

     

    For
      the
      sake of clarity, sales of Product or Marketed Product among DOV, its Affiliates,
      sublicensees or Commercial Partners, where such Product or Marketed Product
      is
      being transferred to such Affiliate, sublicensee or Commercial Partner for
      purposes of resale or further distribution, shall not be included in the
      calculation of Net Sales, it being understood that Net Sales shall be calculated
      based on the gross amount invoiced in connection with such resale or further
      distribution. Notwithstanding, the foregoing, if Product or Marketed Product
      is
      sold or otherwise transferred among DOV, its Affiliates, sublicensees or
      Commercial Partners and DOV, such Affiliate, such sublicensee or such Commercial
      Partner is the end user of such Product or Marketed Product, then the Net Sales
      for such units of Product or Marketed Product shall be calculated based on
      the
      gross amount invoiced in connection with such sale or transfer.

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    
      	1.7.      
                	
              “Patent
                Rights”
                shall mean all patents and patent applications, including, without
                limitation, all provisional applications, substitutions, continuations,
                continuations-in-part, divisions, and renewals, all patents granted
                thereon, and all patents-of-addition, reissues, reexaminations, extensions
                and extended exclusivities (including, without limitation, supplementary
                protection certificates and pediatric extensions) or restorations
                by
                existing or future extension or restoration
                mechanisms.

            

    

     

    
      	1.8.     
                	
              “Product”
                means the compound listed in Schedule 1,
                plus any and all prodrugs, optical isomers, hydrates, solvates, salt
                forms
                and polymorphs of such compound.

            

    

     

    
      	1.9.       
               	
              “Retained
                Rights Field”
                means the treatment or amelioration of vasomotor symptoms caused
                by or
                occurring in relation to or connection with menopause or other female
                hormonal fluctuations in the patient being
                treated.

            

    

     

    
      	1.10.    
                	
              “Scheduled
                Payments”
                means those lump sums payable at the time of the achievement of specific
                developmental activities during the development period through actual
                commercial introduction of a Product following regulatory
                approval.

            

    

     

    
      	1.11.     
               	
              “Subject
                Patent Rights”
                means the patents and patent applications listed in Exhibit C,
                all patents issuing on such patent applications, plus all Patents
                Rights
                that claim priority to, in whole or in part, directly or indirectly,
                one
                or more of any such patents or patent
                applications.

            

    

     

    
      	1.12.    
                	
              “Territory”
                means all countries of the world.

            

    

     

    
      	1.13.     
               	
              “Wyeth
                Know-How”
                means all information, patentable or otherwise, developed, applied,
                or
                acquired by Wyeth as of May 22, 1997 relating to the production or
                development of the Product that is reasonably useful or necessary
                to
                develop or manufacture Product.

            

    

     

    
      	1.14.    
                	
              “Wyeth
                Patents”
                means the Wyeth Primary Patents and the Wyeth Secondary
                Patents.

            

    

     

    
      	1.15.     
               	
              “Wyeth
                Primary Patents”
                means the (i) patents and patent applications listed in Exhibit A,
                (ii) all patents issuing on such patent applications, (iii) all other
                Patents Rights that claim priority to, in whole or in part, directly
                or
                indirectly, one or more of any of the patents or patent applications
                identified in (i) or (ii) above, and (iv) those other Patent Rights
                Controlled by Wyeth or any of its Affiliates, as of the Effective
                Date or
                thereafter during the term of this Agreement, which other Patent
                Rights
                relate solely to and may be used solely for the manufacture or use
                of the
                Product or Marketed Product in the Field, provided,
                however,
                that such other Patent Rights of this clause (iv) shall not include
                (a) any Patent Right directed to or claiming any manufacturing technology
                that is not required for the manufacture of such Product or Marketed
                Product (e.g.,
                if
                the Product or Marketed Product is amenable to being manufactured
                by a
                method that is not covered by the applicable other Patent Right,
                such
                other Patent Right would not be considered to be a Wyeth Primary
                Patent
                for purposes of this Agreement) or (b) any Patent Right directed
                to or
                claiming any pharmaceutical formulation
                technology.

            

    

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    
      	1.16.     
               	
              “Wyeth
                Secondary Patents”
                means all Patent Rights (other than the Wyeth Primary Patents) Controlled
                by Wyeth or any of its Affiliates, as of the Effective Date or thereafter
                during the term of this Agreement, that are necessary for the manufacture,
                use, sale, offer for sale, importation, research, development or
                commercialization or other exploitation of any Product or Marketed
                Product, provided,
                however,
                that such Patent Rights shall not include (i) any Patent Right directed
                to
                or claiming any manufacturing technology that is not required for
                the
                manufacture of such Product or Marketed Product (e.g.,
                if the Product or Marketed Product is amenable to being manufactured
                by a
                method that is not covered by the applicable other Patent Right,
                such
                other Patent Right would not be considered to be a Wyeth Secondary
                Patent
                for purposes of this Agreement) or (ii) any Patent Right directed
                to or
                claiming any pharmaceutical formulation
                technology.

            

    

     

    
      	1.17.    
               	
              “Wyeth’s
                Place of Payment”
                means 500 Arcola Road, Collegeville, Pennsylvania
                19426.

            

    

     

    
      	1.18.    
               	
              As
                used in this Agreement, the singular includes the plural and the
                plural
                includes the singular, wherever appropriate by fact or by
                context.

            

    

     

    Article
      2.0  License
      Grants

     

    
      	2.1.       
               	
              As
                of May 29, 1998, Wyeth hereby grants, for itself and its Affiliates,
                to
                DOV and its Affiliates, an exclusive (even as to Wyeth and its Affiliates)
                license under Wyeth Patents and Wyeth Know-How (a) to make, have
                made and
                develop (subject to Article
                3.4)
                Product and Marketed Product in the Territory and (b) to use, sell,
                offer
                to sell, import and commercialize Product and Marketed Product in
                the
                Field in the Territory.
                For the sake of clarity, DOV shall have no right under the Wyeth
                Patents
                or the Wyeth Know-How to make, have made, and develop any Product
                and
                Market Product in the Retained Rights Field, it being understood
                and
                agreed that Wyeth shall have the sole right to do so, subject to
                Article
                3.4.
                For the sake of clarity, the license granted hereunder with respect
                to a
                Product or Marketed Product shall encompass any metabolite of such
                Product
                or Marketed Product resulting from human administration of such Product
                or
                Marketed Product, but shall not encompass the administration of any
                such
                metabolite as a separate pharmaceutical
                product.

            

    

     

    
      	2.2.         	
              Subject
                to Wyeth’s right of first refusal provided for in Article
                4.0
                and the provisions in Article
                5.0,
                DOV shall have the right to grant sublicenses under the license provided
                for in Article
                2.1.
                DOV shall provide Wyeth with a true, accurate and complete copy of
                each
                such sublicense granted by it promptly after granting such sublicense.
                In
                the event that DOV grants such a sublicense to a third party, Wyeth
                agrees
                to negotiate in good faith and enter into with each of DOV and such
                third
                party a standby license under which Wyeth would grant to such third
                party
                (and DOV would consent to the grant to such third party of), a direct
                license of the rights granted to DOV under Article
                2.1
                above, which direct license (i) would become effective upon the
                termination (but not expiration) of this Agreement for any reason
                other
                than a termination by Wyeth under Article
                13.4
                for an uncured material breach of this Agreement which breach is
                caused in
                whole or in part by the actions or omissions of such third party
                (ii)
                would provide for such third party to promptly cure any breach of
                this
                Agreement remaining uncured at such time of termination, (iii) would
                be on
                the terms and conditions under the sublicense agreement between DOV
                and
                such third party, provided,
                however,
                that in no event shall such terms and conditions be any less favorable
                to
                Wyeth than the terms and conditions of this Agreement and (iv) would
                include other terms and conditions customary for agreements of such
                type.
                It
                is understood and agreed that in consideration for entering into
                any such
                direct license, Wyeth would not require such sublicensee to make
                any
                payments to Wyeth over and above those that would be required under
                clauses (ii) and (iii) above.

            

    

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    
      	2.3.         	
              Without
                limiting the scope of the license granted to DOV under Article
                2.1(a),
                Wyeth retains all rights under the Wyeth Patents and Wyeth Know-How
                to
                use, sell, offer to sell, import, develop and commercialize Product
                and
                Marketed Product in the Territory solely for use in the Retained
                Rights
                Field, in all events subject to Article
                3.4.
                On a country-by-country basis, Wyeth hereby agrees not to commercialize
                Product or Marketed Product for use in the Field for the period during
                which DOV is obligated to pay royalties hereunder on sales of Product
                or
                Marketed Product in such country.

            

    

     

    
      	2.4.         	
              As
                of the Effective Date, DOV hereby grants, for itself and its Affiliates,
                to Wyeth, an exclusive license under the DOV Patents to use, develop,
                sell, offer to sell, import and commercialize Product and Marketed
                Product
                in the Territory solely for use in the Retained Rights Field, in
                all
                events subject to Article
                3.4
                remaining in full force and effect, provided,
                however,
                that the grant of such license shall be subject to the licenses granted
                to
                DOV under Article
                2.1,
                including, without limitation, DOV’s exclusive right under the Wyeth
                Patents and to use the Wyeth Know-How to make, have made and develop
                Product and Marketed Product in the
                Territory.

            

    

     

    Article
      3.0  Developmental
      Activities

     

    
      	3.1.         	
              While
                this Agreement is in effect, DOV shall use reasonable efforts to
                develop
                and commercialize the Product, either through itself or through a
                third
                party commercial partner. Such activities include negotiating the
                terms of
                a sublicense agreement with a third
                party.

            

    

     

    
      	3.2.         	
              DOV
                may disclose unpublished Wyeth Patents and Wyeth Know-How to a third
                party, bound under an obligation of confidentiality that is substantially
                the same as the obligation provided for in Article
                7.0
                of
                this Agreement, to the extent necessary to negotiate a sublicense,
                and
                thereafter to develop and commercialize the
                Product.

            

    

     

    
      	3.3.         	
              On
                a quarterly basis, DOV, upon Wyeth’s request, shall provide Wyeth with a
                written report outlining its developmental activities during that
                quarter.

            

    

     

    
      	3.4.         	
              In
                the event that either party desires either to conduct any clinical
                studies
                of a Product or Marketed Product for use in the Retained Rights Field
                or
                to seek regulatory approval to market and sell Product or Marketed
                Product
                for use in the Retained Rights Field, such party shall notify the
                other
                and the parties shall enter into negotiations for the parties to
                cooperate
                in the development and commercialization of Product and Marketed
                Product
                on mutually agreeable terms for use in the Retained Rights Field,
                provided,
                however,
                that neither party or any of their respective Affiliates or sublicensees
                shall conduct any such research or development or commercialization
                of any
                Product or Marketed Product for use in the Retained Rights Field
                without
                first reaching agreement with the other party, and provided
                further,
                DOV shall not be in violation of this Article
                3.4
                if
                a patient is treated for a disease, condition or disorder falling
                within
                the Retained Rights Field merely incidentally as a result of
                administration of Product or Marketed Product for an indication not
                falling within the Retained Rights Field (provided that for this
                last
                provisio neither DOV, its Affiliates or sublicensees have deliberately
                taken any action, directly or indirectly, to encourage such use of
                a
                Product or Marketed Product).

            

    

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

    Article
      4.0  Wyeth
      Right of First Refusal

     

    
      	4.1.         	
              Prior
                to or simultaneously with beginning discussions with any third party
                regarding a potential Partnering Agreement for Product or Marketed
                Product, DOV may notify Wyeth that DOV is pursuing such discussions
                and
                provide Wyeth with a copy of all data and information in DOV’s possession
                relating to such Product or Marketed Product. Prior to its entering
                into a
                Partnering Agreement with a third party with respect to Product,
                DOV shall
                present, in writing, to Wyeth the bona
                fide
                proposed terms and conditions of said Partnering Agreement
                (the “Third
                Party Term Sheet”).
                Following receipt by Wyeth of the Third Party Term Sheet, Wyeth shall
                have
                thirty (30) days to notify DOV if it intends to enter into a development
                agreement with DOV, the terms of which would exceed those proposed
                by a
                third party by ten percent (10%) relative to Scheduled Payments and
                royalties, provided,
                however,
                that if DOV has not provided Wyeth with the notification, data and
                information as and when contemplated under the first sentence of
                this
                Article
                4.1,
                the thirty (30) day period referenced above in this sentence shall
                be
                changed to sixty (60) days. So as to permit Wyeth to reach such decision,
                DOV shall provide to Wyeth all relevant data and information regarding
                Product available to DOV (which data was not previously provided
                to Wyeth
                as required under the first sentence of this Article
                4.1),
                simultaneously with its providing to Wyeth the terms and conditions
                offered by the said third party.

            

    

     

    
      	4.2.         	
              Upon
                Wyeth’s providing DOV with notification of its intent to enter into an
                agreement with DOV pursuant to Article
                4.1,
                the parties will promptly negotiate said agreement embodying Wyeth’s offer
                under Article
                4.1
                and this Agreement shall terminate upon the effective date of said
                agreement.

            

    

     

    
      	4.3.         	
              If
                Wyeth does not notify DOV of its intention to enter into an agreement
                with
                DOV pursuant to Articles
                4.1
                and
                4.2,
                within the thirty (30) or sixty (60) day period provided for under
                Article
                4.1,
                as applicable, DOV shall be free to enter into a sublicense agreement
                with
                the third party under the terms presented to Wyeth, or
                better.

            

    

     

    
      	4.4.         	
              In
                the event that DOV files a New Drug Application (NDA) in the USA,
                or a
                foreign equivalent thereof in Europe or Japan, but has not yet entered
                into a license agreement with a third party for Product, DOV shall
                provide
                Wyeth with a copy of the NDA (or the foreign equivalent thereof as
                filed
                together with its English translation) for evaluation by Wyeth. If
                Wyeth
                expresses an interest in marketing the Product, then the parties
                shall
                enter into good faith negotiations relating to the possibility of
                Wyeth’s
                obtaining marketing rights to the Product, provided that DOV shall
                not be
                required to grant by this Article
                4.4
                any such rights.

            

    

     

    Article
      5.0  Partnering
      Agreements

     

    
      	5.1.         	
              If
                DOV enters into a Partnering Agreement with a third party with regard
                to
                Product under this Agreement, such Partnering Agreement shall provide
                for
                DOV to receive Scheduled Payments and royalty payments based on Net
                Sales
                of Marketed Product.

            

    

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

     

    Article
      6.0  Payments

     

    
      	6.1.         	
              Within
                thirty (30) days after the Effective Date of the Original License
                Agreement, DOV shall pay Wyeth the fee as indicated below in this
                Article
                6.1
                for exercising its Option rights with regard to each Product. Such
                fee
                shall be non-refundable and non-creditable against any other payments
                due
                Wyeth pursuant to this Agreement:

            

    

     

    
      	
              Bicifadine,
                CL 220,075

            	 	
              $

            	
              150,000

            	 

    

    

    Wyeth
      acknowledges that the fees provided for in this Article
      6.1
      have
      been received.

     

    
      	6.2.         	
              DOV
                shall pay to Wyeth each of the Scheduled Payments set forth below
                within
                thirty (30) days after achievement of the event corresponding to
                such
                Scheduled Payment:

            

    

     

    
      	
              Event

            	 	 	
              Payment

            	 
	
              First
                NDA (or equivalent) filing in the United States, Europe or Japan
                for a
                Product containing Bicifadine, CL 220,075

            	 	
              $

            	
              5,000,000

            	 
	
              NDA
                (or equivalent) approval in the United States, Europe or Japan for
                a
                Product containing Bicifadine,
                CL 220,075 

            	 	
              $

            	
              4,500,000

            	 

    

    

    Notwithstanding
      the foregoing, in the event that DOV grants to a third party a sublicense with
      respect to Product or Marketed Product or otherwise enters into an agreement
      (a “Partnering
      Agreement”)
      with a
      third party (a “Commercial
      Partner”)
      relating to and where such third party has the right to control, in whole or
      in
      part, the development or commercialization of Product or Marketed Product in
      one
      or more countries of the Territory (including, without limitation, any asset
      purchase agreement, joint venture agreement, collaboration agreement,
      copromotion or comarketing agreement, distribution agreement, or license
      agreement, but excluding any agreement where the third party solely provides
      services to DOV in connection with the development of the Product, e.g.,
      a
      clinical trial agreement with a clinical research organization) then, the
      Scheduled Payment set forth above that would become due with respect to such
      Product(s) upon NDA (or equivalent) filing or approval, as the case may be,
      but
      regardless of whether the relevant event actually occurs, shall become
      immediately due and shall be payable by DOV within thirty (30) days. The
      remaining Scheduled Payments, if any, for such Product shall remain payable
      upon
      achievement of the relevant events as set forth above. For the sake of clarity,
      only one Scheduled Payment shall be accelerated per Product.

     

    
      	6.3.         	
              DOV
                shall pay to Wyeth royalties in the amount of five percent (5.0%)
                of all
                Net Sales obtained by DOV or its Affiliates, in connection with the
                sale,
                or distribution or other disposition of Product or Marketed Product
                in the
                Territory.

            

    

     

    Notwithstanding
      the foregoing, if DOV sublicenses the Product or Marketed Product or otherwise
      enters into a Partnering Agreement with any third party relating to the
      development or commercialization of the Product or Marketed Product in one
      or
      more countries of the Territory, DOV shall pay to Wyeth royalties in the amount
      of five and one-half percent (5.5%) of all Net Sales obtained by DOV, its
      Affiliates, sublicensees or Commercial Partners in connection with the sale,
      distribution or other disposition of such Product or Marketed Product in such
      country(ies) (it being understood that for all remaining countries royalties
      would remain payable at the rates set forth above).

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

     

     

    
      	6.4.         	
              DOV
                shall keep and shall obligate its Affiliates, sublicensees and Commercial
                Partners to keep accurate and complete records of all sales of Product
                and
                Marketed Product in accordance with generally accepted accounting
                principles and practices. In any agreement between DOV and a third
                party,
                DOV shall obligate such third party to allow routine audits by Wyeth
                of
                such third party’s records
                relating to the Product and Marketed Product and shall further require
                such third party to likewise obligate any additional third party
                that
                enters into an agreement with the third party relating to the Product
                and
                Marketed Product to allow routine audits by Wyeth of such additional
                third
                party’s records relating to the Marketed Product. Wyeth, no more than one
                time per calendar year for each of DOV or any third party so audited,
                may
                conduct, at its own expense, at reasonable times during normal business
                hours, through an accountant designated by Wyeth and acceptable to
                DOV
                (and its sublicensees and their sublicensees, as appropriate), an
                audit of
                the accounts contemplated above, as well as any supporting instruments
                and
                documents, and may make copies of and extracts from such records
                for the
                sole purpose of ascertaining or verifying the correctness of the
                amounts
                remitted by DOV hereunder. Such accountant shall be required by DOV
                or any
                sublicensee to enter into a reasonably acceptable confidentiality
                agreement, and in no event shall such accountants disclose to Wyeth
                or DOV
                any information other than information relating to or supporting
                the
                accuracy of the payments due from DOV hereunder (and, except to the
                extent
                necessary to support sales data using bundles, in no event information
                that relates to products other than the Product and Marketed Product).
                Each such audit shall be limited to the records and accounts pertaining
                to
                the year on which the audit is conducted and the immediately preceding
                five (5) calendar years. Results in the form of a report of such
                audit
                shall be made available by Wyeth to DOV and to any third party that
                is the
                subject of the audit. Should such audit reveal any discrepancies
                between
                reports made by DOV or its sublicensees and the audit exceeding five
                percent (5%) in favor of DOV or any third party that is audited,
                then DOV
                shall pay in full the costs of such audit requested by Wyeth; otherwise,
                Wyeth shall bear the costs in full for the audit of the records of
                DOV,
                its Affiliates, or its sublicensees. In the event DOV, its Affiliates
                or
                sublicensees (including further sublicensees) conducts an audit of
                any
                sublicensee selling the Marketed Product, DOV shall provide or shall
                cause
                such Affiliate or sublicensee to provide to Wyeth a copy of each
                audit
                report generated in connection
                therewith.

            

    

     

    
      	6.5.         	
              Royalty
                payments shall be due within sixty (60) days of the end of each calendar
                quarter on Net Sales made in that quarter and shall be paid at Wyeth’s
                Place of Payment. Royalties shall accrue in the currency of the country
                in
                which the sale of the Product or Marketed Product is made, and if
                different from U. S. dollars shall be converted into such currency
                using
                the exchange rate appearing in the Wall
                Street Journal
                applicable for the last day of the calendar quarter during which
                the
                royalties accrued.

            

    

     

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    

     

    
      	6.6.         	
              All
                taxes, assessments, fees, and charges, if any, levied under income
                tax
                laws or regulations with respect to payments due Wyeth hereunder
                shall be
                for the account of Wyeth and if required by law to be withheld and
                paid to
                the applicable jurisdiction, may be deducted by DOV from such payments
                due
                to Wyeth. Receipts for all such deducted taxes, assessments, fees
                and
                charges paid by DOV to the taxing authorities shall be secured by
                DOV and
                sent to Wyeth.

            

    

     

    
      	6.7.         	
              In
                case of any delay in payment by DOV to Wyeth not occasioned by force
                majeure, interest at the rate of one percent (1%) per month, assessed
                from
                the thirty-first day after the due date of the said payment, shall
                be due
                Wyeth without any special notice.

            

    

     

    Article
      7.0  Confidentiality

     

    
      	7.1.         	
              If
                during the performance of this Agreement, one party hereto wishes
                to
                disclose information to another that it considers confidential, and
                if the
                receiving party is willing to accept such information, then such
                information may not be subsequently disclosed by the receiving party
                to a
                third party, other than as provided in this Agreement, without the
                written
                permission of the disclosing party. The parties to this Agreement
                shall
                hold in confidence all information and all knowledge, know-how, practices,
                process or other information disclosed or submitted in writing or
                in other
                tangible form that is considered to be confidential for a period
                of five
                (5) years from the date of such disclosure,
                except:

            

    

     

    
      	(a)         	
              information
                that at the time of disclosure is in the public
                domain;

            

    

     

    
      	(b)         	
              information
                that after disclosure is published or otherwise becomes part of the
                public
                domain through no fault of the receiving
                party;

            

    

     

    
      	(c)         	
              information
                that was in the possession of the receiving party at the time of
                disclosure;

            

    

     

    
      	(d)         	
              information
                that is developed by or on behalf of the receiving party independently
                of
                any disclosure to it by the disclosing party hereunder;
                or

            

    

     

    
      	(e)         	
              information
                that is provided to the receiving party by a third party with the
                right to
                so provide.

            

    

     

    Article
      8.0  Adverse
      Experience

     

    
      	8.1.         	
              DOV
                shall keep (and DOV shall cause its sublicensees to keep under terms
                and
                conditions equal to those set forth in this Article
                8.0)
                Wyeth, during the term of this Agreement, promptly and fully informed
                of
                all pharmaceutical, toxicological and clinical findings relating
                to
                adverse experience of the Product or Marketed
                Product.

            

    

     

    
      	8.2.         	
              DOV
                undertakes to notify Wyeth promptly with written confirmation by
                immediate
                telecopy of any information concerning any serious adverse event
                as
                defined by C.I.O.M.S. or the F.D.A. or by the Ministry of Health
&
                Welfare in Japan, as applicable, reasonably associated with clinical
                studies or attributed to the use or application of the Product or
                Marketed
                Product. In any event the above notification shall be made within
                two (2)
                working days after DOV first learns or is advised of all relevant
                information with respect to such serious adverse
                event.

            

    

     

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    

     

    
      	8.3.         	
              DOV
                shall also forward regularly (and usually every six months unless
                the
                parties agree on another period) to Wyeth any information on all
                other
                adverse effects or any difficulty associated with the clinical use,
                studies, investigations, tests and prescription of the Product or
                Marketed
                Product.

            

    

     

    
      	8.4.         	
              DOV
                shall provide upon request the information on estimated patient days
                of
                exposure.

            

    

     

    
      	8.5.         	
              DOV
                shall inform Wyeth, without delay, of any governmental action,
                correspondence or reports to or from governmental authorities that
                may
                affect the situation of the Product or Marketed Product and furnish
                Wyeth
                with copies of any relevant documents relating
                thereto.

            

    

     

    Article
      9.0  Representations
      and Warranties

     

    
      	9.1.         	
              Wyeth
                hereby represents and warrants that it has the right to grant DOV
                the
                license under Article
                2.0
                of
                this Agreement, and that, as of the Signature Date, Wyeth, to the
                best of
                its knowledge, is not a party to any lawsuit, opposition, re-examination
                or interference contesting the validity of the Wyeth Patents.
                Notwithstanding the foregoing, Wyeth makes no other warranties, expressed
                or implied, and Wyeth does not warrant, nor does it entitle any agent,
                officer, employee or representative of Wyeth to warrant, validity,
                enforceability, efficacy, merchantability, fitness for a particular
                purpose or otherwise with respect to Product, Marketed Product or
                Wyeth
                Patent as the case may be.

            

    

     

    
      	9.2.         	
              DOV
                is fully cognizant of Good Laboratory Practices (“GLP”)
                and Good Manufacturing Practices (“GMP”)
                and shall manufacture or have manufactured Product and Marketed Product
                in
                a manner that fully complies with GLP and
                GMP.

            

    

     

    Article
      10.0  Indemnification,
      Liability and Insurance

     

    
      	10.1.    
                	
              DOV
                shall at all times during the term of this Agreement, and thereafter,
                indemnify, defend and hold Wyeth and all its Affiliates and their
                respective directors, officers, partners, employees, servants and
                agents
                harmless from and against any and all claims and expenses, including
                without limitation legal expenses, court costs, and reasonable attorney’s
                fees, arising out of or relating to the death of or actual or alleged
                injury to any person or damage to any third party’s property, and from and
                against any other claim, proceeding, demand, expense, cost and liability
                of any kind whatsoever (collectively “liabilities”)
                resulting from, arising out of or related to Product or Marketed
                Product.

            

    

     

    
      	10.2.       	
              DOV
                shall take all necessary steps, at its own costs, and shall so obligate
                its sublicensee to properly maintain insurance policies to cover
                all
                liabilities to any third party that might be incurred, directly or
                indirectly, as a result of its participation in the performance of
                this
                Agreement.

            

    

     

    
      	10.3.       	
              DOV
                shall maintain (and shall cause its sublicensee to maintain) product
                liability insurance that may include funded self-insurance reserves
                with
                respect to the development, manufacture and sale of Product and Marketed
                Product in such amount as customary in the industry. DOV (and its
                sublicensee) shall maintain such insurance for so long as it continues
                to
                develop, manufacture or sell Product and Marketed Product and thereafter
                for so long as required to cover such manufacture or
                sales.

            

    

     

    DOV
      (and
      its sublicensee) shall name Wyeth as an additional insured on its insurance
      policy. Upon execution of the Original License Agreement DOV has supplied,
      and
      during the term of this Agreement, upon Wyeth’s request, DOV shall supply Wyeth
      with evidence of such coverage, and undertakes to communicate to Wyeth during
      the term of this Agreement any modifications to such coverages.

     

    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

    

     

    Article
      11.0  Use
      of Names/Trademarks/Publicity

     

    
      	11.1.     
               	
              Neither
                party shall use the name or trademarks of the other party in any
                advertising or other form of publicity without the written permission
                of
                the other party.

            

    

     

    
      	11.2.  
                  	
              By
                virtue of this License Agreement, neither party shall acquire any
                right to
                use trademarks, tradedress or other indicia of origin belonging to
                the
                other party, or any of such other party’s
                Affiliates.

            

    

     

    
      	11.3.  
                  	
              The
                timing and content of any press release or other public communications
                relating to this Agreement and the transactions contemplated herein
                shall,
                except as otherwise required by law, be determined jointly by Wyeth
                and
                DOV.

            

    

     

    Article
      12.0  Patent
      Maintenance, Infringements, and Interferences

     

    
      	12.1.    
                	
              Wyeth
                Patents.

            

    

     

    
      	(i)        
               	
              Prosecution
                and Maintenance.
                Wyeth shall be responsible for the preparation, filing, prosecution
                and
                maintenance (including, without limitation, any interferences,
                oppositions, reissue proceedings and reexaminations), of the Wyeth
                Patents. Wyeth shall reasonably consult with DOV with respect to
                the
                preparation, filing, prosecution and maintenance of the Wyeth Primary
                Patents and DOV agrees to reasonably cooperate with Wyeth in such
                activities. Wyeth shall keep DOV advised of the status of such activities
                and shall also inform DOV in a timely manner of any material
                communications Wyeth receives from the relevant patent office with
                respect
                to such activities. Wyeth shall give notice to DOV of any desire
                to cease
                preparation, filing, prosecution or maintenance of any Wyeth Primary
                Patent on a country-by-country basis, and in such case, DOV shall
                have the
                right to elect to continue preparation, filing, prosecution and
                maintenance of such Wyeth Primary Patent. In the event that DOV elects
                to
                continue any such activities for such Wyeth Primary Patent, DOV shall
                reasonably consult with Wyeth with respect thereto and shall consider
                in
                good faith Wyeth’s reasonable views with respect to such activities, and
                Wyeth agrees to transfer to DOV all information reasonably requested
                by
                DOV for DOV to conduct such activities and to otherwise reasonably
                cooperate with DOV in such actions. DOV shall keep Wyeth advised
                of the
                status of such actions and shall also inform Wyeth in a timely manner
                of
                any material communications DOV receives from the relevant patent
                office
                with respect to such activities. Each party shall bear its own costs
                with
                respect to any preparation, filing, prosecution and maintenance of
                any
                Wyeth Patent for which it is responsible. Upon DOV’s reasonable request,
                Wyeth shall consider in good faith prosecuting in a separate Patent
                application any claim(s) concerning Product or Marketed Product that
                if
                separated into a separate Patent would thereby qualify as a “Wyeth Primary
                Patent” under clause (iv) of that definition instead of being
                included in another Wyeth Patent that is a “Wyeth Secondary Patent”
                hereunder, provided that (i) such separation and additional Patent
                shall not adversely affect the patentability, validity or enforceability
                any of the other Wyeth Patents or any other Patents owned or controlled
                by
                Wyeth or any of its Affiliates, and (ii) DOV shall be responsible for
                any incremental out-of-pocket costs incurred by Wyeth for preparing,
                filing, prosecuting and maintaining such additional
                Patent.

            

    

     

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

    

     

    
      	(ii)          	
              Defense.
                In the event that any actions, claims, demands, suits or other legal
                proceedings are brought or threatened to be brought against DOV by
                a third
                party for infringement of such third party’s patent(s) relating to Product
                per se (but not relating to formulation technology or general
                manufacturing technology), by virtue of DOV’s manufacture, use, sale,
                offer for sale, or importation of the Product or Marketed Product
                hereunder, DOV shall notify Wyeth forthwith of the threat or existence
                of
                such actions with sufficient evidence thereof to enable the parties
                to
                prepare an appropriate defense strategy. The parties shall consult
                together as to the action to be taken and as to how the defense will
                be
                handled. DOV shall be responsible for all defense
                costs.

            

    

     

    DOV
      undertakes not
      to make
      any admission of liability to a claimant or plaintiff or his or her legal
      representative or insurer and not to sign any agreement in respect of such
      proceedings without Wyeth’s previous written consent not to be unreasonably
      withheld.

     

    When
      DOV,
      because of the settlement with Wyeth’s consent of the claimed infringement, or a
      final unappealable or non-appealed judgment of a court of competent
      jurisdiction, is required to make payments to one or more third parties to
      obtain a license without which the marketing of the Marketed Product could
      not
      be made in a given country, DOV may deduct up to fifty percent (50%) of such
      payments from the royalty payments due to Wyeth hereunder, provided
      however,
      that in
      no event shall any royalty payment that would otherwise be due to Wyeth be
      reduced by more than fifty percent (50%).

     

    
      	(iii)          	
              Enforcement
                - Wyeth Primary Patents.
                Each party shall promptly inform the other party of any suspected
                infringement of any of the Wyeth Primary Patents in the Field by
                a third
                party and provide the other party with any available evidence of
                such
                suspected infringement.

            

    

     

    DOV
      shall
      have the first right but not the obligation to institute any claim, suit or
      proceeding against an infringer or a presumed infringer of the Wyeth Primary
      Patents in the Field. DOV shall control the prosecution of any such suit or
      claim, including without limitation the choice of counsel and shall settle
      or
      dispose of any such suit or claim, provided,
      however,
      that
      DOV shall have no right to diminish any of the rights retained by Wyeth
      hereunder in settling or disposing of any such suit or claim.
      Wyeth
      shall provide DOV with all reasonable assistance (other than financial), at
      DOV’s expense, required to institute and maintain such proceedings (including,
      without limitation, being a named party to any such suit or claim). In the
      event
      DOV takes action against a presumed infringer of any of the Wyeth Primary
      Patents, DOV shall bear the entire costs of such prosecution and, in the event
      that DOV obtains payment of any recovery, court award or settlement
      (a “Recovery”)
      from
      the third party infringer for infringement of the Wyeth Primary Patents, DOV
      shall pay to Wyeth, after deducting the costs and expenses borne by DOV in
      prosecuting the claim of infringement, either (a) if reasonable royalties are
      recovered, the greater of (x) the royalty Wyeth would have been entitled to
      receive under Article 6 hereof had such allegedly infringing product been sold
      as a Product or Marketed Product under this Agreement or (y) fifty percent
      (50%)
      of the remainder of such Recovery or (b) if lost profits are recovered, the
      greater of (x) twenty-five percent (25%) of the remainder of such Recovery
      or
      (y) the royalty Wyeth would have received hereunder on an amount of Net Sales
      that would generate a profit for DOV in the amount of the remainder of such
      Recovery, and, in the case of either (a) or (b) above, DOV shall be entitled
      to
      retain the remaining amount of such Recovery.

     

    
      
        
        

      

      
        13

        
          

        

      

      
        
        

      

    

     

    Wyeth
      shall have the right, but not the obligation, to enforce the Wyeth Primary
      Patents against any infringer or presumed infringer in the Retained Rights
      Field. Wyeth shall control the prosecution of any such enforcement suit or
      claim, including without limitation the choice of counsel and shall settle
      or
      dispose of any such suit or claim, provided,
      however,
      that
      Wyeth shall have no right to diminish any of the rights granted to DOV hereunder
      in settling or disposing of any such suit or claim.
      DOV
      shall provide Wyeth with all reasonable assistance (other than financial),
      at
      Wyeth’s expense, required to institute and maintain such proceedings (including,
      without limitation, being a named party to any such suit or claim). Wyeth shall
      bear the entire costs of such prosecution and shall be entitled to retain one
      hundred percent (100%) of any Recovery from the third party infringer for any
      such infringement.

     

    
      	 (iv)         	
              Enforcement
                - Wyeth Secondary Patents.
                Each party shall promptly inform the other party of any suspected
                infringement of any of the Wyeth Secondary Patents in the Field by
                a third
                party and provide the other party with any available evidence of
                such
                suspected infringement.

            

    

     

    Wyeth
      shall have the first right, but not the obligation, to enforce the Wyeth
      Secondary Patents against any infringer or presumed infringer thereof. Wyeth
      shall control the prosecution of any such enforcement suit or claim, including
      without limitation the choice of counsel and shall settle or dispose of any
      such
      suit or claim, provided,
      however,
      that
      Wyeth shall have no right to diminish any of the rights granted to DOV hereunder
      in settling or disposing of any such suit or claim.
      DOV
      shall provide Wyeth with all reasonable assistance (other than financial),
      at
      Wyeth’s expense, required to institute and maintain such proceedings (including,
      without limitation, being a named party to any such suit or claim). In the
      event
      Wyeth so elects to enforce any of the Wyeth Secondary Patents against any
      presumed third party infringer thereof, Wyeth shall bear the entire costs of
      such prosecution and, in the event that Wyeth obtains payment of any Recovery
      from the third party infringer for any such infringement, Wyeth shall be
      entitled to retain one hundred percent (100%) of any such Recovery for any
      infringement of the Wyeth Secondary Patents resulting from the manufacture,
      use,
      import, or sale of a product other than a Product or Marketed Product or from
      the manufacture, use, import, or sale of a Product or Marketed Product in the
      Retained Rights Field and, for infringement of any Wyeth Secondary Patents
      as a
      result of the manufacture, use, import or sale of a Product or Marketed Product
      in the Field, Wyeth, after deducting the costs and expenses borne by Wyeth
      in
      taking action against the alleged infringer, shall be entitled to retain either
      (a) if reasonable royalties are recovered, the greater of (x) the royalty Wyeth
      would have been entitled to receive under Article 6 hereof had such allegedly
      infringing product been sold as a Product or Marketed Product under this
      Agreement or (y) fifty percent (50%) of the remainder of such Recovery or (b)
      if
      lost profits are recovered, the greater of (x) twenty-five percent (25%) of
      the
      remainder of such Recovery or (y) the royalty Wyeth would have received
      hereunder on an amount of Net Sales that would generate a profit for DOV in
      the
      amount of the remainder of such Recovery, and, in the case of either (a) or
      (b)
      above, the remaining amount of such Recovery shall be payable to
      DOV.

     

    
      
        
        

      

      
        14

        
          

        

      

      
        
        

      

    

     

    In
      the
      event that Wyeth fails to initiate action to obtain a discontinuance of the
      alleged infringement of the Wyeth Secondary Patents where such infringement
      is a
      result of the manufacture, use, import or sale of a Product or Marketed Product
      in the Field, within one hundred eighty (180) days after notice is given by
      one
      party to the other of such alleged infringement, DOV may, but shall not be
      obligated, to request that Wyeth permit DOV to institute negotiations or legal
      proceedings with respect to such infringement. Wyeth, shall notify DOV within
      sixty (60) days of such request whether it will or will not permit DOV to take
      such action, it being understood and agreed, that such determination may be
      made
      by Wyeth in its sole discretion. In the event Wyeth permits DOV to take such
      action, DOV shall control the prosecution of any such suit or claim, including
      without limitation the choice of counsel and shall settle or dispose of any
      such
      suit or claim (subject to the licenses and retained rights of Article
      2.0).
      Wyeth
      shall provide DOV with all reasonable assistance (other than financial), at
      DOV’s expense, required to institute and maintain such proceedings. In the event
      DOV so elects to enforce the Wyeth Secondary Patents against a third party
      manufacturing, using, selling or importing any Product or Marketed Product
      in
      the Field, DOV shall bear the entire costs of such action and, in the event
      that
      DOV obtains payment of any Recovery, from the third party infringer for any
      such
      infringement, DOV, after deducting the costs and expenses incurred in taking
      such action shall pay to Wyeth either (a) if reasonable royalties are recovered,
      the greater of (x) the royalty Wyeth would have been entitled to receive under
      Article 6 hereof had such allegedly infringing product been sold as a Product
      or
      Marketed Product under this Agreement or (y) fifty percent (50%) of the
      remainder of such Recovery or (b) if lost profits are recovered, the greater
      of
      (x) twenty-five percent (25%) of the remainder of such Recovery or (y) the
      royalty Wyeth would have received hereunder on an amount of Net Sales that
      would
      generate a profit for DOV in the amount of the remainder of such Recovery,
      and,
      in the case of either (a) or (b) above, the remaining amount of such Recovery
      shall be retained by DOV.

     

    In
      the
      event that (i) Wyeth elects not to enforce the Wyeth Secondary Patents against
      a
      third party alleged to be infringing such Wyeth Secondary Patents as a result
      of
      the manufacture, use, import or sale of a Product or Marketed Product in the
      Field, (ii) Wyeth does not permit DOV to enforce the Wyeth Secondary Patents
      against such third party, (iii) neither Wyeth nor DOV (nor any of DOV’s
      Affiliates, licensees or sublicensees) have taken, are taking or plan to take
      action against such third party to enforce a Wyeth Primary Patent or a patent
      owned or controlled by DOV or any of DOV’s Affiliates, licensees or
      sublicensees, and (iv) during a given calendar quarter the units of the
      allegedly infringing product being sold in the country where such infringement
      is occurring amount to twenty-five percent (25%) or greater of the sum of the
      units of Product, Marketed Product and such allegedly infringing product being
      sold in such country, then the royalty payable by DOV to Wyeth under
      Article
      6.3
      hereof
      for sales made in such country during such calendar quarter shall be reduced
      to
      fifty percent (50%) of the royalty that would otherwise be payable under
      Article
      6.3
      hereof
      with respect to sales during such calendar quarter of Product or Marketed
      Product in the country where such infringement is occurring.

     

    
      
        
        

      

      
        15

        
          

        

      

      
        
        

      

    

     

    
      	12.2.  	
              DOV
                Patents.

            

    

     

    
      	(i)          	
              Prosecution
                and Maintenance.
                DOV shall be responsible, at its own expense, for the preparation,
                filing,
                prosecution and maintenance (including, without limitation, any
                interferences, oppositions, reissue proceedings and reexaminations)
                of the
                DOV Patents. Wyeth shall reasonably consult with DOV with respect
                to the
                preparation, filing, prosecution and maintenance of the DOV Patents.
                DOV
                shall keep Wyeth advised of the status of such activities and shall
                also
                inform Wyeth in a timely manner of any material communications DOV
                receives from the relevant patent office with respect to such activities.
                DOV shall give notice to Wyeth of any desire to cease preparation,
                filing,
                prosecution or maintenance of any DOV Patent on a country-by-country
                basis, and in such case, to the extent not in conflict with DOV’s
                obligations under any agreement under which DOV has licensed such
                DOV
                Patent to a third party for use in the Field (as of the Signature
                Date or
                thereafter), Wyeth shall have the right to elect to continue preparation,
                filing, prosecution and maintenance of such DOV Patent. In the event
                that
                Wyeth elects to continue any such activities for such DOV Patent,
                Wyeth
                shall reasonably consult with DOV with respect thereto and shall
                consider
                in good faith Wyeth’s reasonable views with respect to such activities,
                and DOV agrees to transfer to Wyeth all information reasonably requested
                by Wyeth for Wyeth to conduct such activities and to otherwise reasonably
                cooperate with Wyeth in such actions. Wyeth shall keep DOV advised
                of the
                status of such actions and shall also inform DOV in a timely manner
                of any
                material communications Wyeth receives from the relevant patent office
                with respect to such activities. Each party shall bear its own costs
                with
                respect to any preparation, filing, prosecution and maintenance of
                any DOV
                Patent for which it is responsible.

            

    

     

    
      	(ii)          	
              Enforcement.
                Each party shall promptly inform the other party of any suspected
                infringement of any of DOV Patents by a third party and provide the
                other
                party with any available evidence of such suspected infringement.
                DOV
                shall have the sole right, but not the obligation, to institute any
                claim,
                suit or proceeding against an infringer or a presumed infringer of
                the DOV
                Patents in the Field, and the first right, but not the obligation,
                to
                institute any claim, suit or proceeding against an infringer or a
                presumed
                infringer of the DOV Patents in the Retained Rights Field. DOV, at
                its
                sole expense, shall control the prosecution of any such suit or claim,
                including without limitation the choice of counsel and shall settle
                or
                dispose of any such suit or claim, provided,
                however,
                that DOV shall have no right to diminish any of the rights granted
                to
                Wyeth hereunder in settling or disposing of any such claim. Wyeth
                shall
                provide DOV with all reasonable assistance (other than financial),
                at
                DOV’s expense, required to institute and maintain such
                proceedings.

            

    

     

    
      
        
        

      

      
        16

        
          

        

      

      
        
        

      

    

     

    In
      the
      event that DOV fails to initiate action to obtain a discontinuance of the
      alleged infringement of the DOV Patents as a result of the manufacture, use,
      import or sale of a Product or Marketed Product in the Retained Rights Field
      within one hundred eighty (180) days after notice is given by one party to
      the
      other of such alleged infringement, Wyeth, at its own expense, shall have the
      right, but not the obligation, to institute negotiations or legal proceedings
      with respect to such infringement. In such event, Wyeth shall control the
      prosecution of any such suit or claim, including without limitation the choice
      of counsel and shall settle or dispose of any such suit or claim (subject to
      DOV’s involvement), provided,
      however,
      that
      Wyeth shall have no right to diminish any of the rights retained by DOV
      hereunder in settling or disposing of any such suit or claim.
      DOV
      shall provide Wyeth with all reasonable assistance (other than financial),
      at
      Wyeth’s expense, required to institute and maintain such
      proceedings.

     

    In
      the
      event either party enforces the DOV Patents against the manufacture, use, import
      or sale of a Product or Marketed Product in the Retained Rights Field, and
      obtains any Recovery from the alleged third party infringer, the enforcing
      party
      shall be entitled to retain from such Recovery the costs and expenses incurred
      by it in taking action against such third party and the remainder of any
      Recovery shall be retained by Wyeth if Wyeth is the enforcing party or paid
      to
      Wyeth if DOV is the enforcing party.

     

    
      	12.3.    
                	
              Subject
                Patent Rights.
                The parties acknowledge and agree that certain of the Subject Patent
                Rights that each of them owns may be directed to the same inventions
                concerning Product and thus may, during the course of prosecution
                thereof,
                contain conflicting and overlapping claims. In the event that an
                interference proceeding is initiated between any of the U.S. patent
                applications included within the Subject Patent Rights, the parties
                agree
                to meet to discuss a process to amicably resolve such interference
                and to
                cooperate in the resolution thereof, in each case, with the goal
                of having
                a U.S. patent issue to the assignee of the first inventor of the
                invention
                claimed by such conflicting claims, such patent to be subject to
                the
                licenses granted under Article
                2.0
                without payment of any additional
                consideration.

            

    

     

    Article
      13.0  Duration
      and Termination

     

    
      	13.1.    
                	
              This
                Agreement shall be binding on the parties as of the day of its execution
                but shall have no force or effect until either the parties determine
                that
                notification under Title II of the Hart-Scott-Rodino Antitrust
                Improvements Act of 1976, 15 U.S.C. 18a, and the regulations promulgated
                thereunder, 16 C.F.R. 801.1 et seq., is not required or if the parties
                determine that such notification is required, the waiting period
                shall
                have expired or been terminated. If a notification filing is required,
                the
                parties shall, at their own expense, prepare and make all appropriate
                filings. The parties shall cooperate in the antitrust clearance process
                and hereby agree to furnish promptly to the FTC and the Antitrust
                Division
                of the Department of Justice such additional information reasonably
                requested by them in connection with such filings. In the event that
                the
                waiting period has not expired or been terminated within six (6)
                months after the date of signature of this agreement by both parties,
                the
                parties shall revert to their status before signing and this agreement
                shall be of no force and effect, except for Articles 7, 10, and 11,
                which
                shall survive pursuant to their terms. Thereafter, the Agreement
                shall
                continue in full force and effect on a country by country basis until
                the
                later of (i) subject to Article
                12.1(iii),
                the last to expire of any valid and enforceable claims that are now
                issued
                or that issue at any time during the term of this Agreement under
                the
                Wyeth Patents, Subject Patent Rights and/or any DOV
                Patents in
                such country covering the use or sale of Marketed Product sold in
                such
                country, or (ii) a period of ten (10) years following the launch of
                Marketed Product by DOV or any of its sublicensee(s) in such
                country.

            

    

     

    
      
        
        

      

      
        17

        
          

        

      

      
        
        

      

    

     

    
      	13.2.     
               	
              Upon
                expiration of this Agreement with respect to a Marketed Product in
                a
                country of the Territory, the obligations of the parties under
                Article
                3.4
                with respect to such Marketed Product in such country shall no longer
                apply and DOV shall be deemed to have a fully-paid, royalty-free,
                non-exclusive license with the right to make or have made, use or
                sell
                Product and Marketed Product in such country as well as to freely
                utilize
                all data generated hereunder or received from Wyeth by DOV without
                DOV’s
                having further obligation to Wyeth, except for maintaining confidentiality
                as required by Article
                7.1
                of
                this Agreement and performing any obligations that survive expiration
                of
                this Agreement in accordance with Article
                18.7.

            

    

     

    
      	13.3.     
               	
              Subject
                to Article
                18.7,
                DOV shall be free to terminate its rights and obligations under this
                Agreement and surrender and return to Wyeth all rights acquired by
                DOV
                hereunder at any time upon ninety (90) days’ prior written notice to Wyeth
                at which time all license rights granted by Wyeth to DOV hereunder
                shall
                come to an end. Upon Wyeth’s request after any such termination, DOV shall
                assign to Wyeth all regulatory filings and approvals pertaining to
                any
                Product or Marketed Product and transfer to Wyeth all data and information
                in DOV’s possession in connection therewith. Such termination shall have
                no affect on the licenses granted by DOV to Wyeth under
                Article
                2.4
                (subject to Article
                3.4).

            

    

     

    
      	13.4.    
                	
              In
                the event that a party hereto breaches any material condition herein
                contained, the other party may provide a formal written notice of
                such
                breach, requesting rectification within a sixty (60) day period from
                the
                date of receipt of such notice. The party alleged to be in breach
                of this
                Agreement shall either submit a commercially reasonable plan for
                rectification within forty-five (45) days of receipt of notice (if
                the
                breach cannot be rectified within the sixty (60) day period), or
                take
                appropriate steps to remedy the breach if capable of remedy within
                such
                sixty (60) day period. If within the said sixty (60) day period neither
                the aforesaid plan has been submitted, nor the breach cured, the
                party
                alleging breach shall then be entitled to terminate this Agreement,
                thereby surrendering all rights granted to it hereunder, by written
                notice
                to the other party, such termination having immediate effect. Upon
                Wyeth’s
                request after any such termination by Wyeth, DOV shall assign to
                Wyeth all
                regulatory filings and approvals pertaining to any Product or Marketed
                Product and transfer to Wyeth all data and information in DOV’s possession
                in connection therewith. Any termination under this Article
                13.4
                shall have no affect on the licenses granted to Wyeth under
                Article
                2.4
                (subject to Article
                3.4).

            

    

     

    
      
        
        

      

      
        18

        
          

        

      

      
        
        

      

    

     

    
      	13.5.     
               	
              This
                Agreement may be terminated at once by Wyeth giving notice to DOV
                if DOV
                has committed an act of bankruptcy or an order is made or resolution
                passed for the winding up of DOV. Upon Wyeth’s request after any such
                termination by Wyeth, DOV shall assign to Wyeth all regulatory filings
                and
                approvals pertaining to any Product or Marketed Product and transfer
                to
                Wyeth all data and information in DOV’s possession in connection
                therewith. Any termination under this Article
                13.5
                shall have no affect on the licenses granted by DOV to Wyeth under
                Article
                2.4
                (subject to Article
                3.4).

            

    

     

    
      	13.6.     
               	
              In
                the event this Agreement is terminated prior to its full term pursuant
                to
                Article
                13.3
                by
                DOV or pursuant to Articles
                13.4
                or
                13.5
                by
                Wyeth, DOV shall within thirty (30) days of such event transfer to
                Wyeth
                all information, data and know-how of any kind relating to each Product
                and shall authorize the transfer of all governmental approvals for
                the
                Product to Wyeth, in addition to DOV’s right derived from all license
                agreements between DOV and its third party partners relative to Product
                and Marketed Product.

            

    

     

    Article
      14.0  Reports
      and Notices

     

    
      	14.1.     
               	
              Upon
                Wyeth’s request, DOV shall provide Wyeth an annual report summarizing the
                stage of development relating to the Product. Such report shall be
                provided within thirty (30) days of each December 31 during the term
                of
                this Agreement.

            

    

     

    
      	14.2.     
               	
              DOV
                shall notify Wyeth in writing within fifteen (15) days after
                achieving an event that would require that a Scheduled Payment be
                paid by
                a third party to DOV, or by DOV to Wyeth, with respect to a
                Product.

            

    

     

    
      	14.3.    
                	
              Not
                later than sixty (60) days following the end of each quarter, DOV
                will provide Wyeth with a report summarizing the Net Sales of Marketed
                Product in each country in the Territory made by DOV or a third party
                sublicensee of DOV. Such reporting shall begin following the first
                sale of
                Marketed Product in the Territory.

            

    

     

    
      	14.4.     
               	
              Any
                notices or reports required or permitted to be given under this Agreement
                shall be sent by certified or registered mail, or by an equivalent
                service
                that provides verification of delivery, return receipt requested
                to the
                respective party at the address stated below or such address as to
                which
                the parties are subsequently appropriately
                notified:

            

    

     

    

      
        	
                If
                  to Wyeth:

              	
                Wyeth
                  Pharmaceuticals 

              
	 	
                500
                  Arcola Road

              
	 	
                Collegeville,
                  PA 19426

              
	 	
                Attn:
                  Senior Vice President, Licensing

              
	 	 
	 	
                With
                  a copy to:

              
	 	 
	 	
                Wyeth
                  Pharmaceuticals

              
	 	
                500
                  Arcola Road

              
	 	
                Collegeville,
                  PA 19426

              
	 	
                Attn:
                  Vice President and Chief Counsel, Global Business
                  Development

              

      

       

    

    
      
        
        

      

      
        19

        
          

        

      

      
        
        

      

    

     

    
      
        	 	 
	
                If
                  to DOV:

              	
                DOV
                  Pharmaceutical, Inc.

              
	 	
                150
                  Pierce St.

              
	 	
                Somerset,
                  NJ 08873

              
	 	
                Attn:
                  President

              

      

      
        
        

      

    

    Article
      15.0  Assignment

     

    
      	15.1.  
                  	
              This
                Agreement shall be binding upon and inure to the benefit of the parties
                hereto and the successors to substantially the entire business and
                assets
                of the respective parties hereto. Notwithstanding the foregoing,
                either
                party may void this Agreement if the Agreement is assigned for the
                benefit
                of a creditor. This Agreement shall not be assignable by either party
                (except to an Affiliate, or in connection with the acquisition (whether
                by
                merger, consolidation, sale or otherwise) of a party or that part
                of such
                party’s business to which this Agreement relates), without the prior
                written consent of the other party; any other attempted assignment
                is
                void.

            

    

     

    Article
      16.0  Applicable
      Law

     

    
      	16.1.   
                 	
              This
                Agreement shall be governed by and construed according to the laws
                of the
                State of New Jersey, USA.

            

    

     

    Article
      17.0  Force
      Majeure

     

    
      	17.1.    
                	
              None
                of the parties shall be responsible for failure or delay in the
                performance of any of its obligations hereunder due to Force Majeure.
                Force Majeure shall mean any circumstance that, due to an event or
                a legal
                position beyond the party’s reasonable control, renders impossible the
                fulfillment of any of the party’s obligations hereunder, such as, but not
                limited to, acts of God, acts, regulations, or laws of any government,
                war, civil commotion, destruction of facilities or materials by fires,
                earthquakes, or storms, labor disturbances, shortages of public utilities,
                common carriers, or raw materials, or any other cause, or causes
                of
                similar effects, except, however, any economic occurrence. During
                any such
                case of Force Majeure, this Agreement shall not be terminated, but
                only
                suspended and the party so affected shall continue to perform its
                obligations as soon as such case of Force Majeure is removed or
                alleviated. 

            

    

     

    Article
      18.0  Miscellaneous

     

    
      	18.1.     
               	
              This
                Agreement and the Schedule and Exhibits hereto constitute the full
                understanding and entire Agreement between the parties and supersede
                and
                replace any and all prior oral or written understandings and agreements
                with respect to the subject matter hereof, including, without limitation,
                the Prior Amended and Restated License Agreement. This Agreement
                shall not
                be effective until duly signed by officers of both Wyeth and DOV.
                No
                terms, conditions, understandings or Agreements purporting to modify,
                amend or vary this Agreement shall be binding unless made in writing
                and
                signed by the parties hereto. It is mutually agreed that no party
                has
                relied upon any representations or statements of any third party
                except as
                stated herein.

            

    

     

    
      	18.2.       	
              The
                invalidity or unenforceability of an Article or any part of an Article
                of
                this Agreement in any jurisdiction shall not cause the invalidity
                of the
                whole Agreement as to such jurisdiction, and shall not affect the
                validity
                or enforceability of such Article or such part of an Article in any
                other
                jurisdiction. The parties shall replace any Article or part of an
                Article
                found invalid or unenforceable by alternative provisions that shall
                be as
                similar as possible in their conditions with regard to their spirit
                and
                commercial effect. If this Agreement in any jurisdiction is found
                to be
                invalid or unenforceable, the parties shall replace it by an alternative
                agreement that shall be as similar as possible in its conditions
                with
                regard to its spirit and commercial
                effect.

            

    

     

    
      
        
        

      

      
        20

        
          

        

      

      
        
        

      

    

     

    
      	18.3.       	
              The
                failure of either party on any occasion to require the performance
                by the
                other of any provision hereof shall not affect the right of such
                party to
                enforce the same on a subsequent occasion. The waiver by either party
                of
                any breach of any provision hereof shall not be construed to be a
                waiver
                of any succeeding breach of that or any other provision or a waiver
                of the
                provision itself.

            

    

     

    
      	18.4.       	
              This
                Agreement shall not constitute either party as the joint venturer,
                legal
                representative or agent of the other party for any purpose whatsoever.
                Neither party shall have any right or authority to assume or create
                any
                obligation or responsibility
                for or on behalf of the other party or to otherwise bind the other
                party.

            

    

     

    
      	18.5.       	
              The
                parties recognize that this is a master Agreement covering a number
                of
                countries. If for any country in the Territory it becomes necessary
                to
                execute a separate instrument for such country in order to satisfy
                local
                regulatory requirements, the parties shall execute such further instrument
                that shall to the extent permitted by the laws of the country conform
                to
                the terms and conditions of this
                Agreement.

            

    

     

    
      	18.6.       	
              This
                Agreement and the Schedule and Exhibits hereto are originally prepared
                and
                signed in the English language. If any translation into any other
                language
                is legally required for purposes of governmental filings, the parties
                shall arrange for such translation, and the costs thereof shall be
                borne
                by the party legally required to make such filing. In the event of
                any
                question or dispute as to the meaning or interpretation of any term,
                condition or provision of this Agreement, or any Schedule or Exhibit
                hereto, the English language version shall in all events govern for
                all
                purposes whatsoever.

            

    

     

    
      	18.7.       	
              Termination
                of this Agreement for any reason, or expiration of this Agreement,
                shall
                not affect: (i) obligations, including the payment of any Scheduled
                Payments or royalties that have accrued as of the date of termination
                or
                expiration and (ii) rights and obligations that, from the context
                thereof,
                are intended to survive termination or expiration of this Agreement,
                including, without limitation, Articles
                2.2,
                2.4,
                3.4,
                8.2
                -
                8.4,
                12.3,
                14.2
                (with respect to activities occurring prior to such expiration or
                termination),
                14.3
                (with respect to activities occurring prior to such expiration or
                termination) and
                14.4
                and Articles 6 (with respect to any payments resulting from activities
                arising prior to such expiration or termination), 7, 10, 11, 15,
                16 and
                18.

            

    

     

    
      	18.8.       	
              This
                Agreement is executed simultaneously in counterparts, each of which
                shall
                be deemed an original, but all of which shall constitute but one
                and the
                same instrument.

            

    

     

    [remainder
      of this page intentionally left blank]

     

    
      
        
        

      

      
        21

        
          

        

      

      
        
        

      

    

     

    
      	 WYETH HOLDINGS
              CORPORATION	 	 	 DOV PHARMACEUTICAL,
              INC.
	 	 	 	 
	 	 	 	 
	/s/ Ronald
              W. Alice	 	 	/s/ Scott
              Myers
	
              
NAME:Ronald
              W. Alice	 	 	
              
NAME:
              Scott
              Myers
	
              TITLE:  
                Vice
                President
DATE: 
                December
                7, 2006

            	 	 	
              
                TITLE: 
                  Senior Vice President
                  DATE: 
                    December 7, 2006

                

              

            

    

     

    
      
        	WYETH,
                acting through its
                Wyeth
                  Pharmaceuticals Division

              	 	 	 
	 	 	 	 
	 	 	 	 
	/s/ Ronald
                W. Alice	 	 	 
	
                

                NAME:
                  Ronald W. Alice

              	 	 	
              
	
                TITLE: 
                  Vice
                  President

                  DATE: 
                    December
                    7, 2006

                

              	 	 	
              

      

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

    

     

    SCHEDULE
      1

     

    Product

     

    BICIFADINE,
      CL 220,075

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    EXHIBIT
      A

     

    Wyeth
      Patents

     

    Bicifadine,
      CL220,075

     

    United
      States

     

    U.S.
      4,196,120 - expires 4/1/1997

     

    U.S.
      4,231,935 - expires 11/4/1997

     

    U.S.
      4,435,419 - expires 7/1/2001

     

    U.S.
      4.131,611 - expires 12/26/1995

     

    U.S.
      6,204,284 - expires 3/20/2018

     

    US
      2006/0020014 A1

     

    US
      2006/0020015 A1

     

    US
      2006/0019966 A1

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    EXHIBIT
      B

     

    DOV
      Patents

     

    US
      7,094,799B2

     

    US
      2006/0100263

     

    US
      60/702,800

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    EXHIBIT
      C

     

    Subject
      Patent Rights

     

    Certain
      Wyeth Patents:

     

    US
      2006/0020014 A1

     

    US
      2006/0020015 A1

     

    US
      2006/0019966 A1

     

    Certain
      DOV Patents:

     

    US
      2006/0100263

     

    US
      60/702,800

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]